Location: DIBIT1 A3, Floor 2, Room 57
Director, San Raffaele Telethon Institute for Gene Therapy
Group leader, Gene transfer technologies and new gene therapy strategies Unit
Group leader, Targeted cancer gene therapy Unit
Full professor, Vita-Salute San Raffaele University
Luigi Naldini, M.D., Ph.D., is Professor of Cell and Tissue Biology and of Gene and Cell Therapy at the San Raffaele University School of Medicine and Scientific Director of the San Raffaele Telethon Institute for Gene Therapy, Milan, Italy.
He has pioneered the development and applications of lentiviral vectors for gene transfer, which have become one of the most widely used tool in biomedical research and, upon recently entering clinical testing, are providing a long sought hope of cure for several currently untreatable and otherwise deadly human diseases. Since then he has continued to investigate new strategies to overcome the major hurdles to safe and effective gene transfer, translate then into new therapeutic strategies for genetic disease and cancer, and allowed new insights into hematopoietic stem cell function, induction of immunological tolerance and tumor angiogenesis. His work also contributed to advance the use of artificial nucleases for targeted genome editing in cell and gene therapy.
He is Member of the European Molecular Biology Organization (EMBO), has been President of the European Society of Gene and Cell Therapy (ESGCT), and has been appointed as expert on the “Human Gene Editing Study” of the US National Academies of Sciences and of Medicine, and on the Italian National Committee for Biosafety, Biotechnology and Life Sciences. He was awarded a European Research Council Advanced Investigator Grant (ERC) in 2009, the Outstanding Achievement Award from the American Society of Gene and Cell Therapy (ASGCT) in 2014 and from ESGCT in 2015, an Honorary doctorate from the Vrije University, Brussel, in 2015, the Jimenez Diaz Prize in 2016, the Beutler Prize from the American Society of Hematology (ASH) in 2017, the LouisJeantet Prize for Medicine, Lausanne, in 2019 and the Global Health Pioneer Award 2019, Dubai. Nominated “Grande Ufficiale” dell’Ordine “Al Merito della Repubblica Italiana”, from the President of the Republic and the Prime Minister of Italy , on December 27th 2019. He has published 278 scientific papers cited >41,000 times. SCOPUS Author hindex : 97
2003-2008 Co-director, San Raffaele Telethon Institute for Gene Therapy, Milan, Italy
Since 2003 Full Professor of Cell and Tissue Biology, School of Medicine, “Vita-Salute San Raffaele” University
2002-1998 Associate Professor, Torino Univ. Med. School and Director, Laboratory for Gene Transfer and Therapy, Institute for Cancer Research and Treatment, Candiolo (Torino), Italy
1998-1996 Senior Scientist and Director, Cell Genesys, Foster City, CA
1996-1994 Visiting Scientist, The Salk Institute for Biological Studies, La Jolla, CA
1996-1990 Assist. Professor, Dept. of Biomedical Sciences and Oncology, Torino University
2016–2020: Member of the Italian National Advisory Committee on Biosafety, Biotechnology and Life Sciences
Since 2015: Member of the Advisory Committee to the Italian Ministry of Health
2015-2017: Member of the Human Gene Editing Study Committee by the National Academies of Sciences and of Medicine of the USA
Since 2012: President of the European Society of Gene and Cell Therapy (ESGCT)
Since 2008: Member of the Advisory Council of the American Society of Gene and Cell Therapy (ASGCT)
2005-2008 Member of the Board of Directors of the American Society of Gene and Cell Therapy (ASGCT)
Scientific Advisor on EMEA and WHO Committees for the evaluation of novel gene transfer medicines
Served on several Scientific Committees of the ASGCT, ESCGT, American Association of Cancer Research (AACR), International Society for Stem Cell Research (ISSCR), International Society of Cell Therapy (ISCT)
Associate Editor: Human Gene Therapy
Mary Ann Liebert Publisher Member of the Editorial Board: Molecular Therapy, Gene Therapy
2008 Elected Member of EMBO, the European Molecular Biology Organization.
2009 Awarded the European Research Council (ERC) Advanced Investigator Grant, which recognizes top EU scientists with an outstanding achievement track record.
2012 Awarded the Premio Sapio of the Italian Research (Health Area).
Research abstracts submitted from Luigi Naldini’s laboratory to the ASGCT and/or ESGCT Annual Meetings were selected among the top abstracts at the 1999, 2000, 2001, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011 and 2012 annual conferences.
2014 Outstanding Achievement Award from the American Society of Gene and Cell Therapy Human Gene Therapy “Pioneer Award”
2014 Premio Gili Agostinelli for Biological and Medical Sciences from the Accademia delle Scienze di Torino
2015 Honorary doctorate from the Vrije University, Brussel,
2015 Outstanding Achievement Award from the European Society of Gene and Cell Therapy in The Jimenez Diaz Prize, Conchita Rábago de Jiménez Díaz Foundation, Madrid
2016 Premio Capitani, Milan, Italy
2017 The Beutler Prize from the American Society of Hematology (ASH), USA
2019 The Louis-Jeantet Prize for Medicine, Lausanne
2019 The Global Health Pioneer Award, Dubai
2019 Nominated “Grande Ufficiale” dell’Ordine “Al Merito della Repubblica Italiana”, one of the highest ranking honor in Italy, from the President of the Republic and the Prime Minister of Italy , on December 27th
Inventor of 58 granted international patents and 45 pending. These include a cornerstone patent on lentiviral vector technology owned by the Salk Institute and a family originator patent owned by Cell Genesys. Intellectual property recently generated at the San Raffaele Institute covers bidirectional vectors for coordinate gene expression, micro-RNA regulated vectors, angiogenic monocytes and macrophage microRNAs, tolerogenic vectors, vector production and engineering, gene editing technology.
1987-1983 PhD in Cell and Tissue Biology with P.M. Comoglio, Torino University
1983 MD, Torino University